Skip to Main Content

Naftali Kaminski, MD

he/him/his
DownloadHi-Res Photo

About

Titles

Boehringer Ingelheim Pharmaceuticals, Inc. Professor of Medicine (Pulmonary)

Section Chief, Pulmonary, Critical Care & Sleep Medicine

Biography

Dr. Naftali Kaminski is, as of July 1st, 2013, the Boehringer-Ingelheim Endowed Professor of Internal Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine, at Yale School of Medicine. Before that he was a tenured professor of Medicine, Pathology, Computational Biology and Human Genetics, and the Dorothy P. and Richard P. Simmons Endowed Chair for Pulmonary Research at the University of Pittsburgh. Dr. Kaminski was the director of the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease and the Lung, Blood and Vascular Center for Genomic Medicine at the division of Pulmonary, Allergy and Critical Care Medicine in University of Pittsburgh. Dr Kaminski received his medical degree from the Hebrew University - Hadassah Medical School in Jerusalem, Israel, and completed a residency in Internal Medicine at Hadassah Mount-Scopus University Hospital in Jerusalem, and a fellowship in pulmonary medicine at Sheba Medical Center in Tel-Hashomer, Israel. Dr Kaminski received his basic science training in Dean Sheppard's laboratory at the Lung Biology Center at UCSF and in functional genomics and microarray technology at the Functional Genomics laboratory at Roche Bioscience, Palo-Alto. After his fellowship in 2000, Dr. Kaminski was appointed head of Functional Genomics at Sheba Medical Center in Israel, before being recruited to head the Simmons Center at the University of Pittsburgh in 2002.

Dr. Kaminski's main research interests involve applying genomic approaches to elucidate basic mechanisms and improve diagnosis and treatment of Idiopathic Pulmonary Fibrosis (IPF), a chronic mostly lethal and currently untreatable scarring lung disease and other chronic lung diseases such Chronic Obstructive Pulmonary Disease (COPD), severe asthma and sarcoidosis. His group pioneered the application of high throughput genome scale transcript profiling in advanced lung disease. Among his key scientific achievements are: The discovery of novel molecules with significant active roles in pulmonary fibrosis, including matrix metalloproteases (MMP7, MMP19) and phosphatases (SHP2, MKP5) , demonstrating that microRNAs, a family of small non-coding RNAs, are differentially expressed in IPF, and that some of them (let-7, mir-29, mir-33) are mechanistically involved in lung fibrosis, and the discovery that the outcome of patients with IPF can be predicted based on the expression of peripheral blood proteins and genes, a finding with practical implication because of the need for risk stratification and transplant prioritization. More recently Dr. Kaminski's team identified a potential antifibrotic role for thyroid hormone signaling, a novel discovery with significant therapeutic implications, and performed single cell RNA sequencing on >300,000 cells obtained from patients with advanced lung disease and created an online freely available data dissemination tool (www.IPFCellAtlas.com). Dr. Kaminski has a strong interest in integrating high throughput ‘omics’ data, such as genome scale DNA variants, coding and non-coding RNAs, microbiome and metabolome information with clinical information to generate systems biology models of lung diseases and to develop precision medicine approaches that are significantly more precise, predictive and patient-centered than anything that is currently available.

Since completing his clinical training, Dr. Kaminski authored more than 340 research papers (including in Nature Medicine, NEJM, Nature Genetics, Nature Communications, PNAS, Science Advances, Science Translational Medicine, Circulation, Lancet Respiratory Medicine, ARCCM and ERJ among others) review articles and book chapters and has given numerous invited talks at national and international conferences, review articles and book chapters and has given numerous invited talks at national and International conferences. Since he finished his fellowship in 2000, Dr. Kaminski has been consistently funded by NIH and is the PI of multiple NIH grants. Dr. Kaminski was a recipient of the Marvin I. Schwarz Award for contributions to patient care and research in pulmonary fibrosis from the Coalition for Pulmonary Fibrosis in 2010 and the University of Pittsburgh Innovator Award in 2012. In 2013, Dr. Kaminski received the American Thoracic Society Recognition of Scientific Achievements award, as well the Helmholtz Institute International Fellow. In 2015 he was elected to the Association of American Physicians. In 2016 he was elected as Fellow of the European Respiratory Society (ERS), and won the European Respiratory Society Gold medal for Interstitial Lung Disease. In 2018, Dr. Kaminski received the Andy Tager Excellence in Mentorship Award from the Respiratory Cell and Molecular Biology Assembly of the American Thoracic Society and was elected fellow of the American Thoracic Society and received the Yale Blavatnik Innovation Award. In 2022 Kaminski received the American Thoracic Society Amberson Lecture award. Dr. Kaminski is active on the ATS and was the editor of “Gene Express”, a column on genomics in the initial days of the ATS Website, a member and chair of the Program Committee of the Assembly on Respiratory Cell and Molecular Biology of the ATS, and member of the ATS Research Advocacy Committee, and Chair of the Assembly on Respiratory, Cell, and Molecular Biology at the American Thoracic Society. He was an associate editor of the American Journal of Respiratory and Critical care Medicine, a member of multiple editorial boards and recently the Deputy Editor of Thorax, BMJ. Dr. Kaminski served as the President of the Association of Pulmonary, Critical Care and Sleep Division Directors in 2019.

Dr. Kaminski is passionate about training physician-scientists for the challenges of 21st century medicine, and especially in the vocabulary, skills and technology of the new fields of genomics, bioinformatics, computational and system biology and their application to understanding the basic mechanisms that govern lung health and disease as well as to designed personalized medicine approaches and has mentored multiple MD and PhD scientists, of them many have productive and well funded independent career. He has most recently recognized for his commitment to mentoring with the American Thoracic Society Andy Tager excellence in mentoring award.

Follow Dr. Kaminski on Twitter @kaminskimed
Follow Dr. Kaminski on mastodon @kaminskimed@med-mastodon.com

<a rel="me" href="https://med-mastodon.com/@Kaminskimed">Mastodon</a>

Appointments

Education & Training

MD
Hebrew University (1989)
BM
Hebrew University (1985)

Research

Overview

Dr. Kaminski’s team main ambition is to uncover the mechanisms, and thus have a significant impact on the management of advanced lung diseases with a specific focus on IPF, a chronic progressive interstitial lung disease that is currently incurable. To study these mechanisms Dr. Kaminski’s team applies systems biology approaches that incorporate a combination of traditional molecular biology methods, high-throughput genomic technologies such as transcript level profiling (single cell RNA sequencing and epigenomic profiling ) , genome scale analyses of gene variants, advanced bioinformatics approaches and targeted proteomic approaches. These studies have led to shifts in the perception of pulmonary fibrosis, the realization that aberrant activation of developmental pathways is at the core of lung fibrosis, the discovery of the role of microRNAs in IPF, the identification and validation of novel prognostic biomarkers in the bloodstream, as well many additional insights.

Mechanisms of pulmonary fibrosis and other chronic lung diseases

  • Understanding and identifying the genetic and molecular networks that determine the lung phenotype using high throughput high resolution genomic and proteomic technologies.
  • Role of miRNA in advanced lung disease (IPF, Emphysema).
  • Role of other non-coding RNAs (lincRNAs) in advanced lung disease
  • The IPF Cell Atlas (www.IPFCellAtlas.com)
  • The Normal Aging Lung Cell Atlas
  • The Pulmonary Fibrosis Connectome
  • Epigenomics of chronic lung disease.
  • Using computational approaches to Integrate clinical, biological, genomic and proteomic data to identify new molecular phenotypes of disease.

New molecular targets in Pulmonary Fibrosis

  • The role and regulation of microRNAs (let-7, mir-33, mir-29) in human pulmonary fibrosis and development of microRNA inhibitors and agonist for therapeutic interventions
  • The role of large non-coding RNAs in pulmonary fibrosis
  • The role of thyroid hormone signaling in epithelial cell protection in fibrosis
  • Novel lung resident cell specific therapeutic approaches in pulmonary fibrosis

Biomarker Discovery and Validation in chronic and progressive lung disease

  • Approaches to the development of liquid biopsy in human pulmonary fibrosis and other interstitial lung disease
  • Peripheral blood protein markers in lung fibrosis
  • Genetic predictors of outcome in lung fibrosis
  • Peripheral blood gene expression changes and disease progression

Medical Subject Headings (MeSH)

Biomarkers, Pharmacological; Emphysema; Fibrosis; Gene Expression; Genetics, Medical; Genomics; Lung Diseases; Metalloproteases; MicroRNAs; RNA

Research at a Glance

Yale Co-Authors

Frequent collaborators of Naftali Kaminski's published research.

Publications

Featured Publications

2024

Academic Achievements & Community Involvement

  • activity

    New England Journal of Medicine

  • activity

    Nature Medicine

  • activity

    Cell

  • activity

    Public Library of Science (PLoS) Medicine

  • activity

    Proceedings of the National Academy of Sciences (PNAS)

Clinical Care

Overview

Naftali Kaminski, MD, chief of Yale Medicine Pulmonary, Critical Care and Sleep Medicine, is a leader in improving the understanding and treatment of chronic lung diseases. He has a particular interest in idiopathic pulmonary fibrosis, a disease characterized by progressive scarring of the lungs, and in chronic obstructive pulmonary disease and asthma.

Dr. Kaminski leads the Kaminski Lab at Yale School of Medicine, where researchers apply cutting-edge technologies that measure changes in the sequence, expression or regulation of all the genes in the human genome in efforts to learn more about the roles of genome networks and biomarkers in chronic lung disease.

“Pulmonary fibrosis was an understudied and poorly understood disease, with high mortality and morbidity,” says Dr. Kaminiski, who is a professor of medicine (pulmonary) at Yale School of Medicine “I thought that by shifting the focus to human
relevant pathways and mechanisms we can have an impact, and we have.”

Clinical Specialties

Pulmonology & Sleep Medicine

Fact Sheets

Yale Medicine News

Get In Touch

Contacts

Academic Office Number
Office Fax Number
Mailing Address

Pulmonary, Critical Care & Sleep Medicine

300 Cedar Street, TAC-441 South, PO Box 208057

New Haven, CT 06520-8057

United States

Administrative Support

Locations

Events

Dec 202417Tuesday